Welcome to the international HTA database
Showing [20829 Records] Selected Records [0 Hits] [Clear]
Year | Source | Title | |
---|---|---|---|
2005 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [Acupuncture for headache] | |
2005 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [Acupuncture for lateral epicondylitis] | |
2005 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [Acupuncture for treating lumbago] | |
2016 | Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) | [Acute neck and back pain: preventive interventions – Effects of physical training, manual treatment and cognitive behavioral interventions] | |
2013 | German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) | [Acute pain treatment on postoperative and medical non-surgical wards] | |
2006 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [Adalimumab for treating rheumatoid arthritis] | |
2013 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis] | |
2009 | Committee for New Health Technology Assessment (CNHTA) | [ADAMTS 13 Activity] | |
2013 | Basque Office for Health Technology Assessment (OSTEBA) | [Adaptation and assessment of an online research methodology training course for nurses] | |
2010 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | [Adaptation to the Catalan health care system of the clinical practice guideline 'Management of major depression in adults'] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A12-15 Crizotinib] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A12-16 Saxagliptin/metformin] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A12-18 (dapagliflozin)] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-03 (sitagliptin/metformin)] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-05 (fidaxomicin)] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-06 (Abiraterone acetate [New therapeutic indication])] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-09 (vandetanib)] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-10 (pertuzumab)] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-16 (vildagliptin)] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-17 (vildagliptin/metformin)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-33 (enzalutamide)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-35 (dabrafenib)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-37 (regorafenib)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A14-05 (sofosbuvir)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A14-12 (canagliflozin)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A14-14 (dimethyl fumarate)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A14-18 (simeprevir)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A14-19 (mirabegron)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A14-21 (Fingolimod)] | |
2015 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A14-22 (Umeclidinium/vilanterol)] | |
2015 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A14-26 (empagliflozin)] | |
2015 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A14-28 (apixaban)] | |
2015 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to Commission A14-31 (daclatasvir)] | |
2011 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Addendum to the final report A09-02 (benefit assessment of prasugrel)] | |
2014 | Institut national d'excellence en sante et en services sociaux (INESSS) | [Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)] | |
2008 | Committee for New Health Technology Assessment (CNHTA) | [Adenovirus, nested PCR] | |
2006 | The Netherlands Organisation for Health Research and Development (ZonMw) | [Adherence to guidelines in ambulatory patients with mild heart failure and associated organisational factors] | |
2022 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Adjunctive colposcopy technologies (videocolposcopy) for cervical conditions] | |
2016 | National Evidence-based Healthcare Collaborating Agency (NECA) | [Advantages of vestibular rehabilitation on the vestibular neuritis] | |
2013 | Institut national d'excellence en sante et en services sociaux (INESSS) | [Advisability of expanding the Québec newborn blood screening program] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Afamelanotide - Assessment according to §35a (para. 1., sentence 10) Social Code Book V] | |
2021 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Afamelanotide (erythropoietic protoporphyria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Afatinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] | |
2015 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Afatinib (new therapeutic indication) - benefit assessment according to §35a Social Code Book V] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Aflibercept - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] | |
2015 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Aflibercept (Addendum to Commission A14-32)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Aflibercept (extension of approval) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Aflibercept (Eylea) extension of approval - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] | |
2015 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Aflibercept (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Aflibercept (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Aflibercept (Zaltrap) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] | |
2013 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Aflibercept for age-related macular degeneration and central retinal vein occlusion] | |
2009 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | [Age-related macular degeneration: the role of current treatment strategies] | |
2008 | Committee for New Health Technology Assessment (CNHTA) | [AGL gene, mutation[sequencing]] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Albiglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)] | |
2011 | Haute Autorite de sante (HAS) | [Albumin (or protein) to creatinine ratios in the diagnosis of chronic kidney disease in adults] | |
2009 | Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) | [Albumin Dialysis and Molecular Adsorbent Recirculating System (MARS) in the treatment of liver failure] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Albutrepenonacog alfa - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V] | |
2022 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Albutrepenonacog alfa (haemophilia B) - Assessment according to §35a Social Code Book V] | |
2018 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V] | |
2017 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19] | |
2018 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67] | |
2017 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V] | |
2003 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Alefacept (Amevive(R)) for the treatment of severe psoriasis] | |
2016 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Alemtuzumab for multiple sclerosis] | |
2018 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Alemtuzumab in multiple sclerosis] | |
2014 | Andalusian Health Technology Assessment Area (AETSA) | [Alglucosidase alfa (Myozyme ®) in late-onset Pompe disease] | |
2011 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | [Alglucosidase alpha (Myozyme) for treatment of patients with late-onset Pompe disease] | |
2015 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Alipogene tiparvovec - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Alirocumab - Addendum to Commission A15-47] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Alirocumab - Benefit assessment according to §35a Social Code Book V] | |
2019 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)] | |
2019 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Alirocumab for patients with hypercholesterolemia] | |
2012 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Aliskiren / Amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] | |
1999 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Allergic diseases: suggestions concerning organization of prevention, diagnostics and treatment (funded by DIHTA)] | |
2009 | Committee for New Health Technology Assessment (CNHTA) | [Allo skin graft] | |
2021 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Allocation of scarce resources in critical care units in a pandemic] | |
2019 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T-cell non-Hodgkin lymphoma] | |
2018 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Allogeneic T cells (high-risk haematological malignancies) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V] | |
2012 | Andalusian Health Technology Assessment Area (AETSA) | [Allomap genetic test for cardiac transplant rejection] | |
2021 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Alpelisib (breast cancer) - Addendum to Commission A20-81] | |
2020 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Alpelisib (breast cancer) - Benefit assessment according to §35a Social Code Book V] | |
2008 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Alpha1 antitrypsin] | |
2017 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Alprostadil for nonrevascularizable critical lower limb ischemia] | |
2012 | German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) | [Alternative methods for the treatment of post-menopausal troubles] | |
2015 | Haute Autorite de sante (HAS) | [Alternative(s) to 99mTc-sestamibi preoperative scintigraphy for the localization of hypersecreting parathyroid glands in the event of complete shortage of 99mTechnetium (99mTc)] | |
2015 | Norwegian Institute of Public Health (NIPH) | [Alternatives of plasma for transfusion to patients] | |
2001 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Alternatives to blood transfusion] | |
2013 | Basque Office for Health Technology Assessment (OSTEBA) | [Alternatives to short stay psychiatric hospitalisation. Intensive ambulatory monitoring programmes] | |
2010 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | [Ambrisentan (Volibris) in the treatment of pulmonary arterial hypertension] | |
2009 | Committee for New Health Technology Assessment (CNHTA) | [Ambulatory esophageal multichannel impedence pH monitoring] | |
2021 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Ambulatory oxygen therapy in COVID-19] | |
1998 | Basque Office for Health Technology Assessment (OSTEBA) | [Ambulatory ultrasound in Basque country: current status, recommendations on its use and practice] | |
2009 | Committee for New Health Technology Assessment (CNHTA) | [AMH] | |
2010 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | [Amifampridine (Firdapse) for the treatment of Lambert Eaton Myasthenic Syndrome] | |
2021 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Amikacin sulfate (Mycobacterium avium Complex [MAC] lung infections) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V] | |
2022 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Amivantamab (NSCLC) - Benefit assessment according to §35a Social Code Book V] | |
2009 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | [Amotosalen (Intercept) for the inactivation of pathogens for transfusion therapy] |